THE DOWNFALL OF 23ANDME'S BILLION-DOLLAR BET

Summary from the TLDR Founders newsletter

23andMe's journey from biotech darling to bankruptcy reveals the fatal flaws of building on novelty. Despite reaching a $6 billion valuation with its popular DNA testing kits, the company's business model collapsed due to four critical failures: its product was a one-time purchase with no repeat customers, a devastating 2023 data breach exposed 7 million users' genetic information, unclear privacy policies eroded consumer trust, and its attempted pivot to therapeutics failed to deliver a viable second act.